BlackBelt Tx

Therapeutics
Share

Black Belt TX is a preclinical stage biotechnology company focused on translating novel targets in the chronic stress response pathways into new therapeutic approaches to treat cancer. The therapeutic programmes are aimed at key control mechanisms involved in the stress response in the tumour microenvironment. The company has established a diversified pipeline of first-in-class small molecule programmes as well as a proprietary target discovery and validation platform. The company has an experienced team of drug developers and was created as a spin-off from Tusk Therapeutics which was acquired by Roche in September 2018 for 655 million EUR.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.